Bioxcel Therapeutics Inc (BTAI) Stock Price, Quote & News

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 475 238 6837

Website: www.bioxceltherapeutics.com

Address:

555 Long Wharf Drive, 12th Floor, New Haven, United States

Dan1019 Jan. 30 at 9:12 PM

$BTAI When can we expect the FDA to make their decision?

1 · Reply

Dan1019 Jan. 30 at 8:18 PM

$BTAI when moon?

1 · Reply

AllAboutTheBread Jan. 30 at 7:41 PM

$BTAI 63 shares total today 1.52-1.54. what a great haul.

1 · Reply

Weenessie Jan. 30 at 4:11 PM

$BTAI Im bullish on drug and potential here but come on management - anything to keep this alive would be nice now. Its haemoraging.

0 · Reply

AllAboutTheBread Jan. 30 at 4:08 PM

$BTAI bought another 10 shares at 1.53.

1 · Reply

TheInvestorWithNoName Jan. 30 at 3:30 PM

$BTAI Has been and will continue to be a gamble. Strap on your big boy pants and ride the ride with me fellas

0 · Reply

MakeM0ney_444 Jan. 30 at 3:00 PM

$BTAI how many more Pennie’s before delisted ? This management is god awful

1 · Reply

Ernesto62 Jan. 30 at 11:33 AM

$BTAI bullshit

0 · Reply

AllAboutTheBread Jan. 30 at 1:07 AM

$BTAI bought another 10 shares today at 1.62. that alone makes me own more shares than tommytheclown45

1 · Reply

LoganDags620 Jan. 29 at 11:30 PM

$BTAI If the FDA approves the at-home use of IGALMI, the market for acute agitation treatment outside clinical settings could be large because there are currently no FDA-approved at-home options. That could make BTAI attractive to larger pharma firms looking to expand in CNS/neuropsychiatric drugs.

0 · Reply